GlassScriptPhysician profile
Luyuan Li
NPI 1891143301
$59,205.81
in general payments reported to CMS, 2019-2025
20 companies · $3,292 in 2025
The $3,292 reported for 2025 was more than what 76% of Neurological Surgery providers received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $41.78 · 2022: $64.00 · 2023: $55K · 2024: $1,008 · 2025: $3,292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $54K · Food and Beverage: $3,167 · Travel and Lodging: $1,842.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $54,091.00 |
| Food and Beverage | $3,166.54 |
| Travel and Lodging | $1,842.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $25,065.17 | 2023-2025 | Vercise |
| Medtronic, INC. | $20,294.52 | 2021-2025 | Activa PC, Mazor X System, Strata |
| Abbott Laboratories | $9,727.24 | 2023-2025 | Proclaim |
| Insightec,INC | $2,441.93 | 2024-2025 | Exablate |
| Neuropace, INC. | $740.14 | 2024-2025 | |
| Vb Spine LLC | $152.93 | 2025 | Everest Spinal System |
| Orthofix Medical, INC. | $133.78 | 2025 | Trinity Elite |
| Kuros Biosciences USA, INC | $125.36 | 2025 | Magnetos |
| Route 92 Medical, INC. | $118.89 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $98.25 | 2025 | |
| Omniscient Neurotechnology America LTD | $64.00 | 2022 | |
| Stryker Corporation | $50.23 | 2021-2024 | Duramatrix, Universal Neuro 3 |
| Neurelis, INC. | $42.23 | 2024-2025 | Valtoco |
| Globus Medical, INC. | $29.28 | 2024 | Excelsius3d Imaging System |
| Ucb, INC. | $26.96 | 2024 | Fintepla |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $24.65 | 2025 | Rosa |
| Aucta Pharmaceuticals, INC. | $21.85 | 2025 | Motpoly Xr |
| Acadia Pharmaceuticals INC | $17.23 | 2025 | Nuplazid |
| Pacira Pharmaceuticals Incorporated | $16.65 | 2024 | Exparel |
| Depuy Synthes Sales INC. | $14.52 | 2025 | Skyline |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luyuan Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.